Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen CEO Follows President Out the Door

NEW YORK, Feb. 13 - Just three weeks after announcing that its president had left, Deltagen said today that its CEO, William Matthews, had resigned.


Matthews, a co-founder of Deltagen, has served as CEO since 1998.


The office of board chairman Constantine Anagnostopoulos will manage the company until it finds a new CEO, Deltagen said.

The company has been publicly searching for a new CEO since November, after changing course from drug discovery to tools and services, but Matthews was directing day-to-day operations of the transgenic technology company, along with Anagnostopoulos and chief financial officer Richard Hawkins.


Matthews departure is the latest sign that the company, like others in the sector, has been struggling to survive. On Jan. 21, president and chief operating officer Michael Sember left. At the time, GenomeWeb reported that the company had reduced its headcount to 200 and made plans to cut loose its proteomics subsidiary and its Strasbourg, FranceR&D center. In December, the company received a Nasdaq warning letter that it must bring its stock price above that benchmark before March 19 or risk being delisted.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.